This article is more than 5 years old. Information may no longer be current.

Alimera launches pilot study of insert in patients with macular edema secondary to RVO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — Alimera Sciences has begun enrolling patients in a pilot study to assess the safety and efficacy of its Iluvien insert in patients with macular edema due to retinal vein occlusion, the company announced in a press release.

The randomized, double-masked FAVOR (Fluocinolone acetonide for vein occlusion in retina) trial will compare 0.23 µg and 0.45 µg dose concentrations of Iluvien when administered once daily, according to the release.

Alimera expects to receive phase 3 top-line data from its FAME clinical program, which is currently evaluating the safety and efficacy of the insert for treating patients with diabetic macular edema, by the end of the year.